Skip to main content

Foley & Lardner LLP represented TCGX as a co-lead investor in the $200 million private placement financing for Inhibrx, a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases. The round was co-led by RA Capital Management, Viking Global Investors, and Perceptive Advisors.

Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms.

The Foley team was led by partner Louis Lehot and included partners Clyde Tinnen and Lyman Thai, senior counsel Sonia Kothari, and associate Ethan Floyd.

Foley’s Venture & Growth Capital attorneys understand the complex and diverse needs of both venture funds and their portfolio companies and offer a broad range of services at each stage of development. The attorneys have insight into the unique needs of high-growth companies operating in the technology, life science, smart manufacturing, and clean energy sectors.

Foley’s Life Sciences Team is composed of corporate, health care, regulatory, and IP attorneys whose comprehensive approach guides start-ups and established enterprises in the life sciences industry through fluctuating global financial markets, a rapidly changing IP environment, and regulatory hurdles that can impact the products they bring to market. For decades, our attorneys have partnered with life sciences companies at all stages of development to help them make their mark on the industry.

Author Louis Lehot

More Insights by Louis Lehot